AstraZeneca’s nerve disease drug Wainua, made in partnership with U.S.-based Ionis, failed to meet the main goal of reducing cardiovascular deaths and recurring heart problems in a late-stage trial.
The trial was for patients with a type of heart disease that lets protein build-up in the heart disrupt blood pumping and possibly cause heart failure. Adding Wainua to standard care did not provide a statistically significant benefit, the trial found.
Wainua is approved in more than 20 countries to treat patients with polyneuropathy, a life-shortening rare disease that causes nerve damage.
In the late-stage trial, Wainua was being tested in 1,432 patients compared to placebo over 140 weeks.
Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.
